An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer
- PMID: 37644744
- DOI: 10.2174/1874471016666230829100703
An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer
Abstract
Background: Mediastinal lymph node metastasis is an important prognostic factor in non-small cell lung cancer (NSCLC) patients without distant metastases. 18F-2-fluoro-2-deoxy-Dglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is recommended for detecting and staging lymph nodes and distant metastases in NSCLC patients.
Objective: This study aims to investigate whether maximum standardized uptake (SUVmax), mean standardized uptake (SUVmean), metabolic tumor volume (MTV), and tumor lesion glycolysis (TLG) values of the primary tumor measured by 18F-FDG PET/CT in resectable NSCLC can predict preoperative lymph node metastasis.
Methods: This retrospective study included eighty NSCLC patients who underwent preoperative Positron Emission Tomography/Computed Tomography (PET/CT) for diagnosis and staging. The patients were stage I-III and had no distant metastases. Tumor metabolic parameters such as SUVmax, SUVmean, MTV, and TLG at PET/CT imaging were measured for preoperative diagnosis and staging, and the postoperative pathology results of the patients were examined. The pathology results divided patients with and without lymph node metastasis into two groups. The groups were compared with the student's t-test and chi-square test regarding 18F-FDG PET/CT tumor metabolic parameters and other parameters.
Results: Fifteen (18.8%) patients were female, and 65 (81.3%) were male. According to the postoperative pathology results, while 30 (37.5%) patients had lymph node metastasis, 50 (62.5%) did not. There was a significant difference between the groups regarding tumor SUVmax and SUVmean values (p = 0.036, p = 0.045). Overall survival in the N0 group was significantly higher than in the N1 + N2 group (p = 0.034); median survival was 30.2 months in N0 cases and 27.3 months in N1 and N2 groups.
Conclusion: SUVmax and SUVmean values are significantly higher in patients with lymph node metastases than in patients without lymph node metastases, and this finding may provide useful information for predicting lymph node metastasis in patients with resectable NSCLC.
Keywords: 18F-2-fluoro-2-deoxy-D-glucose; Non-small cell lung cancer; lymph node metastasis; maximum standardized uptake value; mean standardized uptake.; positron emission tomography.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.Biomark Med. 2025 Jan;19(2):35-41. doi: 10.1080/17520363.2024.2443379. Epub 2024 Dec 24. Biomark Med. 2025. PMID: 39717963 Free PMC article.
-
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.Eur Radiol. 2024 Sep;34(9):5889-5902. doi: 10.1007/s00330-024-10651-5. Epub 2024 Feb 22. Eur Radiol. 2024. PMID: 38388716 Free PMC article.
-
Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.Cancer Med. 2024 Sep;13(18):e70216. doi: 10.1002/cam4.70216. Cancer Med. 2024. PMID: 39302034 Free PMC article.
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
-
The role of baseline 18F-FDG PET/CT for survival prognosis in NSCLC patients undergoing immunotherapy: a systematic review and meta-analysis.Ther Adv Med Oncol. 2024 Nov 4;16:17588359241293364. doi: 10.1177/17588359241293364. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502406 Free PMC article. Review.
Cited by
-
Advances in lymphatic metastasis of non-small cell lung cancer.Cell Commun Signal. 2024 Apr 2;22(1):201. doi: 10.1186/s12964-024-01574-1. Cell Commun Signal. 2024. PMID: 38566083 Free PMC article. Review.
-
TFAP2A promotes NSCLC malignant progression by enhancing AOC1 transcription.Hereditas. 2025 Aug 14;162(1):156. doi: 10.1186/s41065-025-00524-2. Hereditas. 2025. PMID: 40813717 Free PMC article.
-
Association between the Preoperative Standard Uptake Value (SUV) and Survival Outcomes after Robotic-Assisted Segmentectomy for Resectable Non-Small Cell Lung Cancer (NSCLC).Cancers (Basel). 2023 Nov 12;15(22):5379. doi: 10.3390/cancers15225379. Cancers (Basel). 2023. PMID: 38001639 Free PMC article.
-
Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.Biomark Med. 2025 Jan;19(2):35-41. doi: 10.1080/17520363.2024.2443379. Epub 2024 Dec 24. Biomark Med. 2025. PMID: 39717963 Free PMC article.
-
NAT10 Knockdown Improves Cisplatin Sensitivity in Non-Small Cell Lung Cancer by Inhibiting the TRIM44/PI3K/AKT Pathway.Thorac Cancer. 2025 May;16(9):e70079. doi: 10.1111/1759-7714.70079. Thorac Cancer. 2025. PMID: 40324967 Free PMC article.
References
-
- Ettinger D.S.; Wood D.E.; Aisner D.L.; Akerley W.; Bauman J.; Chirieac L.R.; D’Amico T.A.; DeCamp M.M.; Dilling T.J.; Dobelbower M.; Doebele R.C.; Govindan R.; Gubens M.A.; Hennon M.; Horn L.; Komaki R.; Lackner R.P.; Lanuti M.; Leal T.A.; Leisch L.J.; Lilenbaum R.; Lin J.; Loo B.W.; Martins R.; Otterson G.A.; Reckamp K.; Riely G.J.; Schild S.E.; Shapiro T.A.; Stevenson J.; Swanson S.J.; Tauer K.; Yang S.C.; Gregory K.; Hughes M.; Non-small cell lung cancer, Version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017,15(4),504-535 - DOI - PubMed
-
- Suh Y.J.; Park C.M.; Han K.; Jeon S.K.; Kim H.; Hwang E.J.; Lee J.H.; Paeng J.C.; Lee C.H.; Kim Y.T.; Goo J.M.; Utility of FDG PET/CT for preoperative staging of non -small cell lung cancers manifesting as subsolid nodules with a solid portion of 3 cm or smaller. AJR Am J Roentgenol 2020,214(3),514-523 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical